Digital application for drug product potency target evaluation in biopharmaceutical manufacturing

Author:

Shen Darrick1,Panjwani Shyam1ORCID,Spetsieris Konstantinos1

Affiliation:

1. Bayer Pharmaceuticals Berkeley California USA

Abstract

AbstractBiopharmaceutical manufacturing entails a series of highly regulated steps. The manufacturing of safe and efficacious drug product (DP) requires testing of critical quality attributes (CQAs) against specification limits. DP potency concentration, which measures the dosage strength of a particular DP, is a CQA of great interest. In order to minimize the DP potency out‐of‐specification (OOS) risk, sterile fill finish (SFF) process adjustments may be needed. Varying the potency targets can be one such process adjustment. To facilitate such evaluation, data acquisition and statistical calculations are required. Regularly conducting the OOS risk assessment manually using commercial statistical software can be tedious, error‐prone, and impractical, especially when several alternate potency targets are under consideration. In this work, the development of a novel framework for OOS risk assessment and deployment of cloud‐based statistical software application to facilitate the risk assessment are presented. This application is intended to streamline the assessment of alternate potency targets for DP in biologics manufacturing. The major aspects of this potency targeting application development are presented in detail. Specifically, data sources, pipeline, application architecture, back‐end and front‐end development as well as application verification are discussed. Finally, several use cases are presented to highlight the application's utility in biologics manufacturing.

Publisher

Wiley

Reference13 articles.

1. CFR—Code of federal regulations title 21: database.2023https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.3

2. US FDA.Q8(R2) Pharmaceutical Development. United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) editors.2009.

3. Protein formulation and fill-finish operations

4. Wang W.Potency testing of biopharmaceutical products.2014;https://www.americanpharmaceuticalreview.com/Featured-Articles/169473-Potency-Testing-of-Biopharmaceutical-Products/.

5. US FDA.Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Drug Evaluation and Research (CDER) editors.1999.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3